06:31:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2023
2023-11-13 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 Årsstämma 2023
2023-03-24 Extra Bolagsstämma 2022
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2023-03-13 22:16:39

Qlife Holding interim report for Q4 2022 included aged accounts payable owed to the Finish company Adidan Oy of approximately EUR 0.8 million under short term liabilities and mention of a counter claim against a distributor (Aidian) under contingent assets. Today Qlife announces that Aidian Oy has initiated arbitral proceedings towards Qlife Holding AB's wholly owned subsidiary Qlife ApS in which Aidian claims payment of unpaid invoices of approximately EUR 0.8 million from Qlife. Qlife intends to dispute the claim since Qlife has counterclaims exceeding Aidian's claim.

In 2020, Qlife entered into a cooperation with the Finnish company Aidian Oy. Several agreements between the parties were concluded in 2020 and 2021, according to which Qlife undertook to purchase products and services from Aidian and Aidian undertook to purchase products - including the Egoo.Health device and Sars-CoV2-capsule - from Qlife. A dispute has since arisen between Qlife and Aidian. Aidian has claimed payment from Qlife of approximately EUR 0.8 million, for various products and services. Qlife in turn has disputed Aidian's claim in its entirety on the grounds that Qlife has a counterclaim of approximately EUR 2.2 million against Aidian, i.e., exceeding Aidian's claim by approximately EUR 1.4 million. Qlife's counterclaim is based on Aidian's failure to purchase agreed minimum quantities of products from Qlife.

On 13 March 2023, Qlife received notice that Aidian has initiated arbitration proceedings in Helsinki against Qlife for payment of the above mentioned claim along with interest and legal costs. Qlife intends to dispute Aidian's claim and present its counterclaim in the arbitration proceedings.

Aidian's abovementioned claim is reflected as a liability in Qlife's latest financial report whereas Qlife's counterclaim against Aidian was reported as a contingent asset but was not recorded in the balance sheet.